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Purpose: To evaluate the potential of diffusion kurtosis imaging (DKI) analysis with 
the breath-hold technique to assess the stage or classify hepatic fibrosis.  
Materials and Methods: Patients (n = 67) suspected of having a disease of the 
hepatobiliary system examined by diffusion-weighted imaging (DWI) using a 3.0-T 
magnetic resonance imaging unit were enrolled in this study. To evaluate hepatic 
fibrosis, mean kurtosis, Mean apparent diffusion (MD) and apparent diffusion 
coefficient (ADC) values were compared between groups with varying fibrosis; F0-F1, 
F2-F3, and F4. The Steel–Dwass test was used for overall comparisons. Correlations 
between the fibrosis stage and mean kurtosis, MD or ADC values were assessed using 
Spearman’s rank correlation. Discriminative capacities of DKI were evaluated using 
receiver operating characteristic (ROC) analysis.  
Results: There were significant differences in ADC, MD and mean kurtosis values 
between non-cirrhosis and cirrhosis groups. Moreover, the mean kurtosis value was 
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statistically different between the F0-F1 and F2-F3, F0-F1 and F4, and F2-F3 and F4 
groups (all P < 0.05). MD value was statistically different between the F0-F1 and F4 
groups, and F2-F3 and F4 groups (all P < 0.05). However, there was no significant 
difference in ADC values for all groups (all P > 0.05). In addition, mean kurtosis and 
MD values significantly correlated with the extent of hepatic fibrosis staging 
(Spearman's rank correlation coefficient, ρ = 0.851 and −0.672; P < 0.0001). However, 
ADC values did not reveal a correlation with the extent of hepatic fibrosis staging (ρ = 
−0.227; P = 0.078). According to the ROC analysis for the assessment of no fibrosis 
(F0), fibrosis (≥F1), and advanced fibrosis (≥F2) and liver cirrhosis, the DKI cut-off 
values were 0.923, 0.955, and 1.11, respectively. 
Conclusion: Using the DKI method with the breath-hold technique in the liver, the 
stage of hepatic fibrosis can be classified into normal and early hepatic fibrosis, 
substantial stages, and advanced hepatic fibrosis. 
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Viral hepatitis, alcoholic and nonalcoholic steatohepatitis, and metabolic disorders	
(e.g., hemochromatosis or Wilson’s disease) are the most common types of chronic 
hepatic disease. These chronic hepatic diseases lead to hepatic fibrosis, which may 
develop into cirrhosis and hepatocellular carcinoma in the liver parenchyma [1]. 
Hepatic fibrosis can be cured if detected at an early stage, such as F1 or F2 as per the 
New Inuyama classification system, and treated immediately; however, advanced 
hepatic fibrosis, such as F3 or F4 as per the New Inuyama classification system, is 
difficult to reverse [2], [3]. Therefore, early detection and evaluation of hepatic fibrosis 
is very important. 
Thus far, liver biopsy is the reference standard modality for assessing the degree of 
fibrosis and evaluating necrosis or inflammation. In the New Inuyama classification 
system, chronic hepatic diseases are classified according to the degree of fibrosis (F) as 
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follows: F0 (no fibrosis), F1 (portal fibrosis widening), F2 (portal fibrosis widening 
with bridging fibrosis), F3 (bridging fibrosis plus lobular distortion), and F4 (liver 
cirrhosis) [2].Chronic hepatic diseases are also classified based on the degree of 
inflammation of lymphocytes and necrosis of hepatocytes. In hepatic pathology, 
degeneration by hepatocellular disorder, fatty degeneration, necrosis, and hepatic 
fibrosis are assessed. These degenerations indicate different pathological structures 
because of changes in the cellular density and ultrastructure. Pathologists assess the 
degree of hepatic inflammation and fibrosis using these results. However, liver biopsy is 
an invasive medical procedure and can result in bleeding, pneumothorax, and 
procedure-related death [4]. Furthermore, liver biopsy is not used for follow-up 
assessments because of excessive physical and mental burden on patients. The 
procedure also has additional limitations including sampling error and inter- or 
intraobserver variability [5]. Therefore, there is a clinical need for alternative 
 8 
noninvasive methods that are quantitative and reproducible for hepatic fibrosis 
diagnosis. 
Magnetic resonance imaging (MRI), such as MR elastography [6], diffusion-weighted 
imaging (DWI), and dynamic contrast-enhanced MRI [1], is a noninvasive tool that 
provides information on the whole liver. Among these methods, DWI has been 
previously used to evaluate inflammation and fibrosis [7], where a lower apparent 
diffusion coefficient (ADC) value indicates a tendency of advanced fibrosis and 
inflammation, such as cirrhotic liver [1], [7]–[13]. The ADC value is calculated using 
monoexponential analysis of conventional DWI data [14]. However, a limitation of 
using ADC values to evaluate hepatic fibrosis is the inadequate detection of each stage 
of hepatic fibrosis [15]. Conventional DWI assumes Gaussian behavior in water 
molecule diffusion [16]; however, somatic structures are complex and many factors 
affect the decay of the diffusion signal, such as water restriction by hepatocellular 
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structures, intra- and extracellular water exchange, and variation in tissue compartment 
sizes.  
Diffusion kurtosis imaging (DKI), which is a non-Gaussian DWI technique using water 
diffusion, has emerged as an advanced method for evaluating the tissue microstructure 
in vivo [17], [18]. DKI analysis described by Jensen et al does not require complete 
diffusion displacement probability distribution [18]; hence, the technique is less 
demanding in terms of acquisition time and gradient strengths. Therefore, the DKI 
method can be easily implemented with the breath-hold technique as an additional 
sequence to evaluate hepatic fibrosis. Analysis of the liver using the DKI method with 
the breath-hold technique may enable us to obtain new and more detailed information 
than conventional DWI. 
Therefore, the purpose of this study was to evaluate the potential of DKI analysis with 
the breath-hold technique for assessing the stage or classifying hepatic fibrosis. 
 10 
2. Materials and Methods 
2.1. Subjects 
This retrospective study was approved by our Institutional Review Board and informed 
consent was waived. Between April 2015 and May 2017, 67 patients (31 men and 36 
women; mean age, 58 years; range, 24–80 years) suspected of having a disease of the 
hepatobiliary system and who had undergone liver MRI, including DWI, were enrolled 
in this study. For the pathologic evaluation of hepatic fibrosis, the liver tissue was 
obtained by percutaneous or intraoperative excisional liver right lobe biopsy or surgery 
following liver MRI. On percutaneous liver biopsy, two tissue samples were obtained 
from the right lobe using an 18-gauge gun. Liver tissues were stained with 
hematoxylin-eosin (HE) (Fig. 1). All pathologic specimens were reviewed by a 
pathologist. Fibrosis was scored on a five-point scale according to the New Inuyama 
classification system [2]: F0, no fibrosis (n = 25); F1, mild and portal fibrosis (n = 7); 
F2, substantial and periportal fibrosis (n = 4); F3, advanced and septal fibrosis without 
 11 















2.2. Diffusional Kurtosis Analysis 
Kurtosis is a dimensionless statistical metric for quantifying the non-Gaussianity of an 
arbitrary probability distribution. We were able to use the breath-hold method for DKI 
acquisition because of its short acquisition time, remove artifacts by macroscopic 
physiological motions, and analyze DKI at the same slice position of each b-value. The 
value obtained by DKI is represented by the mean kurtosis value, which is related to the 
properties of the tissue microstructure, such as tissue complexity and tortuosity of the 
extracellular space [20], [21]. All patients underwent MRI using a 3-T unit (Achieva; 
Philips Medical Systems, the Netherlands) equipped with a six-channel cardiac coil. 
DKI was acquired using a single-shot, spin echo EPI sequence with two diffusion 
weightings (b = 1000 and 2000 mm2/s) along three noncolinear directions and one b = 0 
mm2/s volume (TR, 2500 ms; TE, 58 ms; flip angle, 90°; field of view, 400 × 400 mm2; 
matrix, 80 × 80; slice thickness, 5.0 mm; no intersection gap; parallel imaging factor, 
2.0; and acquisition time, 22 s). In previous studies, Goshima et al. [22] and Sheng et al. 
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[23] have set the maximum b-value to 2000 mm2/s. In addition, because we used the 
breath-hold method for DKI acquisition, few number of b-value was necessary. Hence, 
we used above b-values, as recommended by Jensen et al. [18] for DKI analysis as a 
preliminary study. The gradient length (δ) and time between the two leading edges of 
the diffusion gradient (Δ) were kept constant (Δ/δ = 40/20.5 ms). K map images were 
generated on a voxel-by-voxel basis with DKE software [24], [25] based on following 
formula [18]: 
𝑆	 = 	 𝑆$𝑒𝑥𝑝 (−𝑏𝐷	 +	16 𝑏/𝐷/𝐾1 
where S is the signal intensity at a given b factor, S0 represents the signal in the absence 
of any diffusion weighting, D represents the corrected apparent diffusion coefficient 
accounting for non-Gaussian diffusion behavior, and K represents the apparent kurtosis 
coefficient. Using this calculation, the program outputs maps for MD (mean apparent 
diffusion) and mean kurtosis. The mean kurtosis is defined as the average of the kurtosis 
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over all possible diffusion directions. Similarly, MD is defined as the average of the 
apparent diffusion in all diffusion directions. In this study, ADC values were separately 
calculated using data from b = 0 and b = 800 s/mm
2 only based on conventional DWI 
(note: b 800 images were acquired as low b-values except for DKI analysis). ADC 
values were calculated using the following formula: 
𝐴𝐷𝐶	 = 	 ln 𝑆𝑆$ (−𝑏)8  
where S is the signal intensity at a given b factor, S0 represents the signal in the absence 






2.3. Image Analysis 
Regions of interest (ROI) were placed in the posterior segment of the right hepatic lobe 
to avoid major vessels, large bile ducts, liver edges, and motion artifacts without 
knowing the histopathological results. To measure the same areas, all ROI (round shape, 
at least 10 mm in diameter) were placed in the liver and copied and pasted onto 
T2-weighted MR and diffusion kurtosis images. The mean kurtosis values were 
obtained using commercially available software (MRI cro) [26] and calculated from the 
mean value of five consecutive slices of the liver. The slices were composed of two 
anterior slices, a center slice, and two posterior slices. The center was determined as the 






2.4. Statistical Analysis 
All statistical analyses were performed using JMP (version 11.0 for Macintosh, SAS) 
[27]. To evaluate hepatic fibrosis, ADC, MD and mean kurtosis values obtained in three 
directions (frequency encoding, phase encoding, and section select) were compared 
between groups with varying fibrosis: stages F0, F1, F2, F3, and F4. Differences 
between the non-cirrhosis (F0–F3) and cirrhosis (F4) groups were also determined. The 
Steel–Dwass test was used for multiple non-parametric comparisons of overall values. 
Correlations between the fibrosis stage and mean kurtosis, MD and ADC values were 
assessed using Spearman’s rank correlation. Discriminative capacities of DKI were 
evaluated using receiver operating characteristic (ROC) analysis. The area under the 
curve (AUC) and optimal cut-off value were calculated for the detection of fibrosis 
(≥F1), advanced fibrosis (≥F2), and liver cirrhosis (F4). The cut-off value was estimated 
using the Youden index where (sensitivity + specificity − 1) becomes the maximum 
value. A P value of <0.05 was considered statistically significant. 
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3. Results 
Among the 67 patients enrolled, a pathologist medically diagnosed 42 patients as 
having hepatic fibrosis and 25 patients as not having hepatic fibrosis. The causes of 
hepatic fibrosis in these patients were as follows: hepatitis C virus (n = 17), alcoholic 
steatohepatitis (n = 6), and nonalcoholic steatohepatitis (n = 19; Table 1). 
ADC, MD and mean kurtosis values were significantly different between the 
non-cirrhosis and cirrhosis groups (Fig. 2). Moreover, the mean kurtosis value was 
statistically different between the F0-F1 and F2-F3 group, F0-F1 and F4 group, and 
F2-F3 and F4 group (all P < 0.05; Fig. 3). The MD value was statistically different 
between the F0-F1 and F4 groups, and F2-F3 and F4 groups (all P < 0.05; Fig. 2). In 
MD, unlike the result of the mean kurtosis value, there was no significant difference 
between F0-1 and F2-3 groups. There was no significant difference in ADC values 
according to each group classification (all P > 0.005). Fig. 4 shows four representative 
DKI maps and the mean kurtosis values for each stage of fibrosis. Mean kurtosis and 
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MD values significantly correlated with the extent of staging in hepatic fibrosis 
(Spearman's rank correlation coefficient, ρ = 0.851 and −0.672, and p < 0.0001). 
However, ADC values did not reveal a correlation with the extent of staging in hepatic 
fibrosis (Spearman's rank correlation coefficient, ρ = −0.227, and p = 0.078). According 
to the ROC analysis for the assessment of no fibrosis (F0) and fibrosis (≥F1), AUC, 
cut-off value, sensitivity, and specificity of DKI were 0.936, 0.923, 85.0%, and 96.0%, 
respectively. In advanced fibrosis (≥F2), AUC, cut-off value, sensitivity, and specificity 
of DKI were 0.959, 0.955, 90.9%, and 93.8%, respectively. In liver cirrhosis, the AUC, 
cut-off value, sensitivity, and specificity of DKI were 0.946, 1.11, 85.0%, and 95.6%, 







The results of this study indicate that DKI can be used to distinguish a liver with early 
stage (F0-F1) hepatic fibrosis from one with substantial stages of hepatic fibrosis 
(F2-F3) or advanced stage of hepatic fibrosis (F4). In addition, mean kurtosis values 
significantly correlated with the extent of staging in hepatic fibrosis. Generally, hepatic 
fibrosis manifests as a reaction to a disorder associated with the hepatic histology [1]; 
there is an increase in fibrous connective tissues during the progression of inflammatory 
disorders with cellular degeneration or necrosis [28]. During the fibrotic process, 
deposition of collagen molecules, glycosaminoglycans, and proteoglycans occur in the 
extracellular space of the liver, and as a consequence, this process of hepatic fibrosis is 
a clinical feature of chronic inflammatory disorders. Accordingly, liver fibrosis 
accompanied by hepatocyte swelling and inflammatory cell infiltration can lead to the 
narrowing of the extracellular space, which increases the mean kurtosis value. In 
addition, hepatic cells are capable of regeneration; therefore, they can regenerate 
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completely if cellular degeneration is a transient hepatic dysfunction [29]. The stage of 
progression in hepatic fibrosis is the result of an imbalance between the regeneration 
and degeneration of hepatic cells. With respect to the staging of hepatic fibrosis, 
progression from F0 to F4 indicates an activated inflammatory state that exceeds 
hepatocellular regeneration, which explains the positive correlation between the fibrosis 
staging and mean kurtosis value of the liver. However, each histopathological diagnosis 
within the same fibrosis stage is different because the pathomechanism of hepatic 
fibrosis caused by alcoholic, nonalcoholic, inflammatory, and fatty liver disease differ 
[30]. Consequently, due to this difference in histopathological diagnosis, we considered 
that the range of mean kurtosis value obtained by liver cirrhosis (F4) was wide. 
With respect to the assessment techniques, there are unavoidable issues of sampling 
errors by the operator and inter- or intraobserver variability by a pathologist when 
performing liver biopsy [5]. Specifically, the evaluation results of the same sample may 
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vary among observers. Moreover, evaluation results may be different when an observer 
performs evaluation of the same sample multiple times. These also depend on the years 
of experience and ability of the pathologist who performs the evaluation or on the 
sampling error of the pathological specimen to be evaluated and its difficulty level. 
However, when using DKI analysis, the whole liver can be analyzed rather than a 
localized region, providing a statistical quantification image. Therefore, DKI analysis is 
a more reproducible method than needle biopsy. Furthermore, the method can correctly 
evaluate the structure of the cellular tissue (i.e., the degree of cellular deviation) by 
referring to the DKI cut-off value obtained. 
In this study, the ADC value could only help in differentiating between non-cirrhosis 
and cirrhosis groups, whereas the DKI analysis showed significant differences between 
all hepatic fibrosis groups. In MD, unlike the results of the mean kurtosis value, there 
was no significant difference between F0-1 and F2-3 groups. DKI analysis or MD is 
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based on the assumption that the water diffusion is non-Gaussian in vivo, unlike 
conventional DWI. Thus, MD or DKI can assess the diffusional restriction of the water 
molecules inside the cell with more precision. Furthermore, the deviation from the 
normal distribution is statistically quantified in DKI analysis. Hence, DKI analysis can 
evaluate complicated structure change such as the narrowing of the extracellular space 
by liver fibrosis accompanied by hepatocyte swelling and inflammatory cell infiltration, 
accurately as a numerical value. Anderson et al. [31] assessed animal models of hepatic 
fibrosis using DKI and showed that DKI analysis was a superior model fit compared 
with the stretched exponential or monoexponential model. Therefore, we believe that 
the superior performance of DKI analysis in diagnosing the stage of hepatic fibrosis 
compared with the conventional ADC and MD could provide clinical availability for 
follow-up examination of chronic liver diseases. Moreover, Jensen et al. [18] reported 
that the analysis of kurtosis can be calculated from fewer b-values. Hence, we could use 
the breath-hold method for DKI acquisition and reduce the acquisition time using fewer 
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b-values. Therefore, this method can be easily included as an additional test with routine 
MRI enabling early detection of hepatic fibrosis. The DKI method with the breath-hold 
technique may render it possible to obtain new and more detailed information regarding 
hepatic metabolism or degeneration disorders. 
This study has several limitations. First, the patient population of each group was 
relatively small. Hence, detailed analysis between each fibrosis stages was not achieved.  
Because this study was performed as a preliminary study, the sample size was small was 
used. Further studies with a larger patient number are needed in future. Second, the 
spatial resolution was very low in DKI analysis. In the MRI system used in this study, 
the resolution was limited owing to distortion due to increase in sampling time and 
decrease in the signal to noise ratio, this resolution is the limit. Therefore, we plan to 
improve the pulse sequence with a shorter sampling time, high spatial resolution, and 
lower noise than in the current series in the future by using a new imaging method and 
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MRI system. Third, the location of the pathological specimen obtained by percutaneous 
or intraoperative excisional liver and the position of the ROI obtained from the image 
do not exactly have the same position. Not all liver conditions, such as liver fibrosis and 
hepatic inflammation, are uniform in the same state. Coexistence of F3 and F4, or F2 
and F3 states in the same liver can be also considered sufficiently. Therefore, the 
distribution ranges of diffusion kurtosis values obtained from the liver in different 
stages have the potential to overlap. Finally, we specifically focused on the fibrosis 
stage and did not compare other hepatocellular conditions, such as hepatitis C virus 
infections. There is a continuing need for an in-depth comparison of histopathological 
analyses. 
In conclusion, using the DKI method with the breath-hold technique in the liver, the 
stage of hepatic fibrosis can be classified into normal and early hepatic fibrosis, 
substantial stages, and advanced hepatic fibrosis.  
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Fig.1 Hematoxylin-eosin staining (original magnification 40×) the New Inuyama 
classification system: A) F0, no fibrosis; B) F1, mild and portal fibrosis; C) F2-3, 
substantial and periportal fibrosis and advanced and septal fibrosis without cirrhosis; 
and D) F4, widespread fibrosis and cirrhosis. 
Fig. 2 Comparison of ADC, MD and mean kurtosis values between non-cirrhosis (F0–
F3) and cirrhosis (F4) groups. ADC, MD and mean kurtosis values were significantly 
different between the two groups. 
 
Fig. 3 Comparison of ADC, MD and mean kurtosis values measured in patients with 
hepatic fibrosis stages F0–F1, hepatic fibrosis stages F2–F3, and hepatic fibrosis stages 
F4. Mean kurtosis values were statistically different between F0-F1 and F2-F3, F0-F1 
and F4, and F2-F3 and F4 groups (all P < 0.05). ADC values for each classification 
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were not significantly for all groups (P > 0.05). MD value was statistically different 
between the F0-F1 and F4 groups, and F2-F3 and F4 groups (all P < 0.05).  
 
Fig. 4 Representative DKI maps of each stage of fibrosis. (a) F0-F1 stage of fibrosis 
(mean kurtosis value = 0.74), (b) F2 stage of fibrosis (mean kurtosis value = 0.87), (c) 
F3 stage of fibrosis (mean kurtosis value = 1.09), and (d) F4 stage of fibrosis (mean 
kurtosis value = 1.19). The lower row of images shows the original DKI map. The 
upper row of images shows the color map used to make a visual assessment of the 
difference in values between organizations easier. The mean kurtosis value was defined 






















































































































































































































































Comparing hepatic histopathology and Mean kurtosis, MD and ADC value
Subjects




ADC value ( × 10-3 mm2/S )
Average 
MD value ( × 10-3 mm2/S )
F0 25 0.843 ± 0.051 1.131 ± 0.117 0.862 ± 0.054
F1 7 0.901 ± 0.116 1.112 ± 0.152 0.780 ± 0.088
F2 4 0.910 ± 0.060 1.127 ± 0.166 0.843 ± 0.071
F3 9 1.076 ± 0.064 1.146 ± 0.125 0.743 ± 0.096
F4 22 1.155 ± 0.105 1.055 ± 0.134 0.700 ± 0.058
Note.
Fibrosis staging based on the New Inuyama classification system; F0–F4
ADC, apparent diffusion coefficient; MD, mean apparent diffusion
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